- 专利标题: Ketamine treatment for amyotrophic lateral sclerosis
-
申请号: US17770543申请日: 2021-05-14
-
公开(公告)号: US12128012B2公开(公告)日: 2024-10-29
- 发明人: Richard Barohn , John A. Stanford , Matthew Macaluso
- 申请人: University of Kansas
- 申请人地址: US KS Lawrence
- 专利权人: UNIVERSITY OF KANSAS
- 当前专利权人: UNIVERSITY OF KANSAS
- 当前专利权人地址: US KS Lawrence
- 代理机构: MASCHOFF BRENNAN
- 国际申请: PCT/US2021/032519 2021.05.14
- 国际公布: WO2021/231905A 2021.11.18
- 进入国家日期: 2022-04-20
- 主分类号: A61K31/135
- IPC分类号: A61K31/135 ; A61P25/28
摘要:
A method of treating amyotrophic lateral sclerosis (ALS) is provided to extend life expectancy in a subject. The method can include administering the ketamine to a subject having ALS such that the subject has an extended life expectancy compared to life expectancy of the subject prior to being administered the ketamine. The extended life expectancy is determined by the subject having a first progression rate of ALS prior to being administered ketamine and a second progression rate of ALS after being administered ketamine. The first progression rate is faster than the second progression rate such that the progression of ALS in the subject is slowed by the ketamine.
公开/授权文献
- US20230066347A1 KETAMINE TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS 公开/授权日:2023-03-02
信息查询